Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catheter PrecisionFRA:4RM 27 3-Year EBITDA Growth Rate is 84.80% as of Jun. 2026, which is 1% below its 10-year median of 85.75. GuruFocus rates FRA:4RM with a GF Score™ of 27/100 and a GF Value™ of €783.51. The stock has 9 warning signs investors should review. Among 689 Medical Devices & Instruments companies, Catheter Precision ranks better than 97.39% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 84.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Catheter Precision was 86.70% per year. The lowest was 84.80% per year. And the median was 85.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Catheter Precision 3-Year EBITDA Growth Rate Related Terms
FRA:4RM vs ODYY, BJDX, RBOT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Catheter Precision's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catheter Precision 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Catheter Precision's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 84.80% mean?
Catheter Precision (FRA:4RM) has a 3-Year EBITDA Growth Rate of 84.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Catheter Precision and its competitors. This is near median its historical median of 85.75. Over the past decade, Catheter Precision's 3-Year EBITDA Growth Rate has ranged from 84.80 to 86.70. According to the industry distribution chart, Catheter Precision ranks #18 out of 689 companies in the Medical Devices & Instruments industry, placing it in the top 2.6%.
Is Catheter Precision's 3-Year EBITDA Growth Rate too high?
Catheter Precision's current 3-Year EBITDA Growth Rate of 84.80% is near median its 10-year median of 85.75. Over the past 10 years, this metric has ranged from a low of 84.80 to a high of 86.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Catheter Precision's value of 84.80% is 1001.3% above this industry median. Based on the distribution chart, Catheter Precision ranks #18 out of 689 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Catheter Precision has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's 3-Year EBITDA Growth Rate compare to ODYY and BJDX?
According to the Medical Devices & Instruments industry distribution chart, Catheter Precision ranks #18 out of 689 companies for 3-Year EBITDA Growth Rate. This places Catheter Precision in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.70. Catheter Precision's value of 84.80% is 1001.3% above this benchmark. Historically, Catheter Precision's own 3-Year EBITDA Growth Rate has ranged from 84.80 to 86.70 over the past decade. While the company's 10-year median is 85.75 vs. the industry median of 7.70, Catheter Precision has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catheter Precision's current 3-Year EBITDA Growth Rate of 84.80% is 1001.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Catheter Precision and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catheter Precision's current 3-Year EBITDA Growth Rate is 84.80%, which is near median its own 10-year median of 85.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Catheter Precision (FRA:4RM) has a current 3-Year EBITDA Growth Rate of 84.80%. The stock's GF Value™ is €783.51, compared to a current price of €100.89 — trading 87.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 84.80%, which is near median its 10-year median of 85.75 and 1001.3% above the Medical Devices & Instruments industry median of 7.70. Catheter Precision's overall GF Score™ is 27/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Catheter Precision (FRA:4RM), the current 3-Year EBITDA Growth Rate is 84.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catheter Precision (FRA:4RM) Overvalued in 2026?
Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued.
The current stock price of €100.89 is trading 87.1% below its estimated GF Value™ of €783.51.
Key valuation signals for FRA:4RM:
3-Year EBITDA Growth Rate: 84.80% (near median its 10-year median of 85.75)
GF Value™: €783.51 vs. price of €100.89 (87.1% below fair value)
Industry Position: 1001.3% above the Medical Devices & Instruments median (#18 of 689)
No single metric tells the full story. See the FRA:4RM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
27GF Score
Get the complete analysis for FRA:4RM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RM has been successfully added to your 
